Strain Name:

B6.C-H2-Ab1bm12/KhEg-Mc1re-J/J

Stock Number:

003625

Order this mouse

Availability:

Cryopreserved - Ready for recovery

Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6.C-H2bm12/KhEg-Mc1re-J/J    (Changed: 30-JUL-07 )
Type Coisogenic; Congenic; Major Histocompatibility Congenic; Mutant Strain;
Additional information on Genetically Engineered and Mutant Mice.
Visit our online Nomenclature tutorial.
Additional information on Congenic nomenclature.
Specieslaboratory mouse

Appearance
black
Related Genotype: a/a +/? or a/a Mc1re-J/+

yellow with black eyes
Related Genotype: a/a Mc1re-J/Mc1re-J

Development
The Mc1re-J mutation arose spontaneously on the B6(C)-H-2bm12/KhEgJ background (stock #001162) at The Jackson Laboratory in 1998 when that strain was at generation N10F49. The mutation was shown to be an allele of Mc1r by allele testing with C57BL/6J-Mc1re/J (stock #000060). This strain has been maintained by sibling mating, predominantly heterozygote x homozygote and vice versa, and in 2004 reached generation F49+F18.

Control Information

  Control
   Heterozygote from the colony
 
  Considerations for Choosing Controls

Related Strains

Strains carrying   H2-Ab1bm12 allele
001162   B6(C)-H2-Ab1bm12/KhEgJ
View Strains carrying   H2-Ab1bm12     (1 strain)

View Strains carrying other alleles of H2-Ab1     (14 strains)

Strains carrying other alleles of Mc1r
001434   C3HeB/FeJ x STX/Le-Mc1rE-so Gli3Xt-J Zeb1Tw/J
001533   C3HeB/FeJ-Mc1rE-so Gli3Xt-J/J
000060   C57BL/6J-Mc1re/J
001000   RBD/DnJ
000726   RBF/DnJ
000807   RBJ/DnJ
000729   STOCK Rb(11.13)4Bnr/J
View Strains carrying other alleles of Mc1r     (7 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested.
Albinism, Oculocutaneous, Type II; OCA2   (MC1R)
Melanoma, Cutaneous Malignant, Susceptibility to, 5; CMM5   (MC1R)
View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI
      assigned by genotype

Mc1re-J/Mc1re-J

        B6.C-H2-Ab1bm12/KhEg-Mc1re-J/J
  • behavior/neurological phenotype
  • abnormal pain threshold
    • small (average 5.5%) but significant increase in the minimum alveolar concentration of anesthetic that prevents movement in response to noxious stimuli in 50% of subjects (MAC)   (MGI Ref ID J:105413)
  • pigmentation phenotype
  • *normal* pigmentation phenotype
    • mice exhibit wild-type iris pigmentation   (MGI Ref ID J:141035)
  • integument phenotype
  • abnormal pain threshold
    • small (average 5.5%) but significant increase in the minimum alveolar concentration of anesthetic that prevents movement in response to noxious stimuli in 50% of subjects (MAC)   (MGI Ref ID J:105413)
View Research Applications

Research Applications
This mouse can be used to support research in many areas including:

H2-Ab1bm12 related

Immunology, Inflammation and Autoimmunity Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers

Mc1re-J related

Dermatology Research
Color and White Spotting Defects
      red hair color
Skin and Hair Texture Defects

Endocrine Deficiency Research
Skin Defects

Genes & Alleles

Gene & Allele Information provided by MGI

 
Allele Symbol H2-Ab1bm12
Allele Name b haplotype mutation 12
Allele Type Spontaneous
Common Name(s) H-2bm; H2bm12; bm12;
Strain of Origin(C57BL/6 x BALB/c)F1
Gene Symbol and Name H2-Ab1, histocompatibility 2, class II antigen A, beta 1
Chromosome 17
Gene Common Name(s) A beta; AI845868; Abeta; Bb; CELIAC1; H-2Ab; H2-Ab; HLA-DQB; I-Ab; I-Abeta; I-region-associated antigen 2; IAb; IDDM1; Ia-2; Ia2; RT1.B; Rmcs1; expressed sequence AI845868; histocompatibility 2, class II antigen A, beta; response to metastatic cancers 1;
General Note Genbank ID for this allele: M54876
Molecular Note Three non-consecutive nucleotide changes occurred, resulting in three amino acid substitutions in the beta1 exon. The amino acid changes consist of codon 67 (isoleucine to phenylalanine), codon 70 (arginine to glutamine) and codon 71 (threonine to lysine). These changes were likely the product of gene conversion of H2-Ab1b with sequence from H2-Ebb. [MGI Ref ID J:100015] [MGI Ref ID J:109266] [MGI Ref ID J:99766] [MGI Ref ID J:99767]
 
Allele Symbol Mc1re-J
Allele Name recessive yellow Jackson
Allele Type Spontaneous
Strain of OriginB6(C)-H2-Ab1bm12/KhEgJ
Gene Symbol and Name Mc1r, melanocortin 1 receptor
Chromosome 8
Gene Common Name(s) CMM5; MSH-R; Mshra; SHEP2; Tob; e; extension recessive yellow; extension, recessive yellow; melanocyte hormone receptor alpha; tobacco darkening;
Molecular Note This mutation arose spontaneously at the Jackson Laboratory in 1998. It was shown to be an allele of Mc1r by a noncomplementation test with C57BL/6J-Mc1re/J.

Genotyping

Genotyping Information


Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Additional References

H2-Ab1bm12 related

Adams CO; Housley WJ; Bhowmick S; Cone RE; Rajan TV; Forouhar F; Clark RB. 2010. Cbl-b-/- T Cells Demonstrate In Vivo Resistance to Regulatory T Cells but a Context-Dependent Resistance to TGF-{beta}. J Immunol 185(4):2051-8. [PubMed: 20624942]  [MGI Ref ID J:162386]

Adoro S; McCaughtry T; Erman B; Alag A; Van Laethem F; Park JH; Tai X; Kimura M; Wang L; Grinberg A; Kubo M; Bosselut R; Love P; Singer A. 2011. Coreceptor gene imprinting governs thymocyte lineage fate. EMBO J 31(2):366-77. [PubMed: 22036949]  [MGI Ref ID J:180236]

Anderson BE; Taylor PA; McNiff JM; Jain D; Demetris AJ; Panoskaltsis-Mortari A; Ager A; Blazar BR; Shlomchik WD; Shlomchik MJ. 2008. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. Blood 111(10):5242-51. [PubMed: 18285547]  [MGI Ref ID J:135662]

Ardehali A; Fischbein MP; Yun J; Irie Y; Fishbein MC; Laks H. 2002. Indirect alloreactivity and chronic rejection. Transplantation 73(11):1805-7. [PubMed: 12085005]  [MGI Ref ID J:77397]

Auerbach MB; Shimoda N; Amano H; Rosenblum JM; Kish DD; Farber JM; Fairchild RL. 2009. Monokine induced by interferon-gamma (MIG/CXCL9) is derived from both donor and recipient sources during rejection of class II major histocompatibility complex disparate skin allografts. Am J Pathol 174(6):2172-81. [PubMed: 19389928]  [MGI Ref ID J:148781]

Azzi J; Skartsis N; Mounayar M; Magee CN; Batal I; Ting C; Moore R; Riella LV; Ohori S; Abdoli R; Smith B; Fiorina P; Heathcote D; Bakhos T; Ashton-Rickardt PG; Abdi R. 2013. Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells. J Immunol 191(5):2319-27. [PubMed: 23913965]  [MGI Ref ID J:205809]

Blazar BR; Carreno BM; Panoskaltsis-Mortari A; Carter L; Iwai Y; Yagita H; Nishimura H; Taylor PA. 2003. Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism. J Immunol 171(3):1272-7. [PubMed: 12874215]  [MGI Ref ID J:120213]

Boenisch O; D'Addio F; Watanabe T; Elyaman W; Magee CN; Yeung MY; Padera RF; Rodig SJ; Murayama T; Tanaka K; Yuan X; Ueno T; Jurisch A; Mfarrej B; Akiba H; Yagita H; Najafian N. 2010. TIM-3: a novel regulatory molecule of alloimmune activation. J Immunol 185(10):5806-19. [PubMed: 20956339]  [MGI Ref ID J:165781]

Brown GR; Lee EL; El-Hayek J; Kintner K; Luck C. 2005. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol 174(8):4688-95. [PubMed: 15814693]  [MGI Ref ID J:109999]

Brown GR; Thiele DL. 2000. Enhancement of MHC class I-stimulated alloresponses by TNF/TNF receptor (TNFR)1 interactions and of MHC class II-stimulated alloresponses by TNF/TNFR2 interactions Eur J Immunol 30(10):2900-7. [PubMed: 11069072]  [MGI Ref ID J:65234]

Burchill MA; Yang J; Vogtenhuber C; Blazar BR; Farrar MA. 2007. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178(1):280-90. [PubMed: 17182565]  [MGI Ref ID J:141932]

Chen X; Das R; Komorowski R; Beres A; Hessner MJ; Mihara M; Drobyski WR. 2009. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114(4):891-900. [PubMed: 19491393]  [MGI Ref ID J:150726]

Chiang BL; Bearer E; Ansari A; Dorshkind K; Gershwin ME. 1990. The BM12 mutation and autoantibodies to dsDNA in NZB.H-2bm12 mice. J Immunol 145(1):94-101. [PubMed: 2358682]  [MGI Ref ID J:104189]

Choudhury A; Cohen PL; Eisenberg RA. 2010. B cells require 'nurturing' by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus. Clin Immunol :. [PubMed: 20381429]  [MGI Ref ID J:160847]

Choudhury A; Maldonado MA; Cohen PL; Eisenberg RA. 2005. The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 174(12):7600-9. [PubMed: 15944260]  [MGI Ref ID J:100787]

Christadoss P; Lindstrom JM; Melvold RW; Talal N. 1985. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics 21(1):33-8. [PubMed: 3917973]  [MGI Ref ID J:100213]

Cohen PL; Creech E; Nakul-Aquaronne D; McDaniel R; Ackler S; Rapoport RG; Sobel ES; Eisenberg RA. 1993. Antigen nonspecific effect of major histocompatibility complex haplotype on autoantibody levels in systemic lupus erythematosus-prone lpr mice. J Clin Invest 91(6):2761-8. [PubMed: 7685774]  [MGI Ref ID J:12587]

Cuda CM; Zeumer L; Sobel ES; Croker BP; Morel L. 2010. Murine lupus susceptibility locus Sle1a requires the expression of two sub-loci to induce inflammatory T cells. Genes Immun 11(7):542-53. [PubMed: 20445563]  [MGI Ref ID J:186900]

D'Addio F; Riella LV; Mfarrej BG; Chabtini L; Adams LT; Yeung M; Yagita H; Azuma M; Sayegh MH; Guleria I. 2011. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol 187(9):4530-41. [PubMed: 21949023]  [MGI Ref ID J:179439]

Denaro M; Hammerling U; Rask L; Peterson PA. 1984. The Eb beta gene may have acted as the donor gene in a gene conversion-like event generating the Abm 12 beta mutant. EMBO J 3(9):2029-32. [PubMed: 6436017]  [MGI Ref ID J:99766]

Erlebacher A; Vencato D; Price KA; Zhang D; Glimcher LH. 2007. Constraints in antigen presentation severely restrict T cell recognition of the allogeneic fetus. J Clin Invest 117(5):1399-411. [PubMed: 17446933]  [MGI Ref ID J:122071]

Fischbein MP; Ardehali A; Yun J; Schoenberger S; Laks H; Irie Y; Dempsey P; Cheng G; Fishbein MC; Bonavida B. 2000. CD40 signaling replaces CD4+ lymphocytes and its blocking prevents chronic rejection of heart transplants. J Immunol 165(12):7316-22. [PubMed: 11120867]  [MGI Ref ID J:118395]

Ford MS; Young KJ; Zhang Z; Ohashi PS; Zhang L. 2002. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med 196(2):261-7. [PubMed: 12119351]  [MGI Ref ID J:120698]

Gauba V; Grunewald J; Gorney V; Deaton LM; Kang M; Bursulaya B; Ou W; Lerner RA; Schmedt C; Geierstanger BH; Schultz PG; Ramirez-Montagut T. 2011. Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids. Proc Natl Acad Sci U S A 108(31):12821-6. [PubMed: 21768354]  [MGI Ref ID J:176026]

Gavin MA; Clarke SR; Negrou E; Gallegos A; Rudensky A. 2002. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 3(1):33-41. [PubMed: 11740498]  [MGI Ref ID J:109187]

Graubert TA; DiPersio JF; Russell JH; Ley TJ. 1997. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 100(4):904-11. [PubMed: 9259590]  [MGI Ref ID J:42355]

Gur H; Mendel I; Kerlero de Rosbo N; Ben-Nun A. 1999. Effect of the bm12 class II mutation on proliferative and cytokine responses of encephalitogenic T cells in myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis. J Autoimmun 13(1):3-10. [PubMed: 10441162]  [MGI Ref ID J:56654]

Hansen TH; Melvold RW; Arn JS; Sachs DH. 1980. Evidence for mutation in an I-A gene. Nature 285(5763):340-1. [PubMed: 7374785]  [MGI Ref ID J:99769]

Huygen K; Drowart A; Harboe M; ten Berg R; Cogniaux J; Van Vooren JP. 1993. Influence of genes from the major histocompatibility complex on the antibody repertoire against culture filtrate antigens in mice infected with live Mycobacterium bovis BCG. Infect Immun 61(6):2687-93. [PubMed: 8500908]  [MGI Ref ID J:13022]

Infante AJ; Levcovitz H; Gordon V; Wall KA; Thompson PA; Krolick KA. 1992. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. J Immunol 148(11):3385-90. [PubMed: 1375242]  [MGI Ref ID J:1026]

Karachunski PI; Ostlie N; Bellone M; Infante AJ; Conti-Fine BM. 1995. Mechanisms by which the I-ABM12 mutation influences susceptibility to experimental myasthenia gravis: a study in homozygous and heterozygous mice. Scand J Immunol 42(2):215-25. [PubMed: 7631155]  [MGI Ref ID J:29106]

Kelly LM; Pereira JP; Yi T; Xu Y; Cyster JG. 2011. EBI2 guides serial movements of activated B cells and ligand activity is detectable in lymphoid and nonlymphoid tissues. J Immunol 187(6):3026-32. [PubMed: 21844396]  [MGI Ref ID J:179238]

Keszei M; Detre C; Castro W; Magelky E; O'Keeffe M; Kis-Toth K; Tsokos GC; Wang N; Terhorst C. 2013. Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1-isoform of the Slamf6 receptor. FASEB J 27(8):3123-31. [PubMed: 23629864]  [MGI Ref ID J:203566]

Keszei M; Detre C; Rietdijk ST; Munoz P; Romero X; Berger SB; Calpe S; Liao G; Castro W; Julien A; Wu YY; Shin DM; Sancho J; Zubiaur M; Morse HC 3rd; Morel L; Engel P; Wang N; Terhorst C. 2011. A novel isoform of the Ly108 gene ameliorates murine lupus. J Exp Med 208(4):811-22. [PubMed: 21422172]  [MGI Ref ID J:177322]

Klein J; Figueroa F. 1981. Polymorphism of the mouse H-2 loci. Immunol Rev 60:23-57. [PubMed: 7030925]  [MGI Ref ID J:164060]

Klein J; Figueroa F; David CS. 1983. H-2 haplotypes, genes and antigens: second listing. II. The H-2 complex. Immunogenetics 17(6):553-96. [PubMed: 6407984]  [MGI Ref ID J:7097]

Kosuge H; Suzuki J; Haraguchi G; Koga N; Maejima Y; Inobe M; Isobe M; Uede T. 2006. Critical role of inducible costimulator signaling in the development of arteriosclerosis. Arterioscler Thromb Vasc Biol 26(12):2660-5. [PubMed: 16990558]  [MGI Ref ID J:128034]

Kraj P; Pacholczyk R; Ignatowicz L. 2001. Alpha beta TCRs differ in the degree of their specificity for the positively selecting MHC/peptide ligand. J Immunol 166(4):2251-9. [PubMed: 11160279]  [MGI Ref ID J:126970]

Krco CJ; Beito TG; David CS. 1992. Determination of tolerance to self E alpha peptides by clonal elimination of H-2E reactive T cells and antigen presentation by H-2A molecules. Transplantation 54(5):920-3. [PubMed: 1440860]  [MGI Ref ID J:3237]

Lamouse-Smith E; McCarthy SA. 1997. Allospecific cytotoxic T cells generated from beta 2m-/- mice in primary MLC: analysis of activation requirements, specificity, and phenotype. Cell Immunol 179(2):107-15. [PubMed: 9268494]  [MGI Ref ID J:42696]

Le Moine A; Flamand V; de Lavareille A; Paulart F; Buonocore S; Vanderhaeghen ML; Nagy N; Habran C; Kiss R; Abramowicz D; Goldman M. 2002. Hypereosinophilic syndrome induced by neonatal immunization against MHC class II alloantigen: critical role of IL-4. Eur J Immunol 32(1):174-81. [PubMed: 11754358]  [MGI Ref ID J:73934]

Le Moine A; Surquin M; Demoor FX; Noel JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D. 1999. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice. J Immunol 163(7):3778-84. [PubMed: 10490975]  [MGI Ref ID J:118717]

Leibnitz RR; Lipsky PE; Thiele DL. 1995. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides. J Immunol 155(4):1784-95. [PubMed: 7636234]  [MGI Ref ID J:28656]

Li D; Tsang JY; Peng J; Ho DH; Chan YK; Zhu J; Lui VC; Xu A; Lamb JR; Tam PK; Chen Y. 2012. Adiponectin mediated MHC class II mismatched cardiac graft rejection in mice is IL-4 dependent. PLoS One 7(11):e48893. [PubMed: 23155424]  [MGI Ref ID J:195019]

Li H; Kaplan DH; Matte-Martone C; Tan HS; Venkatesan S; Johnson K; Demetris AJ; McNiff J; Shlomchik MJ; Shlomchik WD. 2011. Langerhans cells are not required for graft-versus-host disease. Blood 117(2):697-707. [PubMed: 20944073]  [MGI Ref ID J:168422]

Li H; Matte-Martone C; Tan HS; Venkatesan S; McNiff J; Demetris AJ; Jain D; Lakkis F; Rothstein D; Shlomchik WD. 2011. Graft-versus-host disease is independent of innate signaling pathways triggered by pathogens in host hematopoietic cells. J Immunol 186(1):230-41. [PubMed: 21098219]  [MGI Ref ID J:168013]

Lobo PI; Bajwa A; Schlegel KH; Vengal J; Lee SJ; Huang L; Ye H; Deshmukh U; Wang T; Pei H; Okusa MD. 2012. Natural IgM anti-leukocyte autoantibodies attenuate excess inflammation mediated by innate and adaptive immune mechanisms involving Th-17. J Immunol 188(4):1675-85. [PubMed: 22262657]  [MGI Ref ID J:181303]

Ma Z; Chen F; Madaio MP; Cohen PL; Eisenberg RA. 2006. Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J Immunol 177(10):7444-50. [PubMed: 17082664]  [MGI Ref ID J:139428]

Ma Z; Choudhury A; Kang SA; Monestier M; Cohen PL; Eisenberg RA. 2008. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 127(2):168-75. [PubMed: 18325838]  [MGI Ref ID J:133606]

Maeda Y; Reddy P; Lowler KP; Liu C; Bishop DK; Ferrara JL. 2005. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood 106(2):749-55. [PubMed: 15797996]  [MGI Ref ID J:107458]

Mathewson N; Toubai T; Kapeles S; Sun Y; Oravecz-Wilson K; Tamaki H; Wang Y; Hou G; Sun Y; Reddy P. 2013. Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood 122(12):2062-73. [PubMed: 23863900]  [MGI Ref ID J:202233]

McIntyre KR; Seidman JG. 1984. Nucleotide sequence of mutant I-A beta bm12 gene is evidence for genetic exchange between mouse immune response genes. Nature 308(5959):551-3. [PubMed: 6324001]  [MGI Ref ID J:100015]

McKean DJ; Melvold RW; David C. 1981. Tryptic peptide comparison of Ia antigen alpha and beta polypeptides from the I-A mutant B6.C-H-2bm12 and its congenic parental strain B6. Immunogenetics 14(1-2):41-51. [PubMed: 6948771]  [MGI Ref ID J:100194]

McKenzie IF; Morgan GM; Sandrin MS; Michaelides MM; Melvold RW; Kohn HI. 1979. B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse. J Exp Med 150(6):1323-38. [PubMed: 159937]  [MGI Ref ID J:99770]

Melvold RW; Wang K; Kohn HI. 1997. Histocompatibility gene mutation rates in the mouse: a 25-year review. Immunogenetics 47(1):44-54. [PubMed: 9382920]  [MGI Ref ID J:44711]

Mendel I; Gur H; Kerlero de Rosbo N; Ben-Nun A. 1999. Experimental autoimmune encephalomyelitis induced in B6.C-H-2bm12 mice by myelin oligodendrocyte glycoprotein: effect of MHC class II mutation on immunodominant epitope selection and fine epitope specificity of encephalitogenic T cells. J Neuroimmunol 96(1):9-20. [PubMed: 10227420]  [MGI Ref ID J:100211]

Mengle-Gaw L; Conner S; McDevitt HO; Fathman CG. 1984. Gene conversion between murine class II major histocompatibility complex loci. Functional and molecular evidence from the bm 12 mutant. J Exp Med 160(4):1184-94. [PubMed: 6434690]  [MGI Ref ID J:109266]

Murray SE; Polesso F; Rowe AM; Basak S; Koguchi Y; Toren KG; Hoffmann A; Parker DC. 2011. NF-kappaB-inducing kinase plays an essential T cell-intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J Clin Invest 121(12):4775-86. [PubMed: 22045568]  [MGI Ref ID J:184029]

Nagano H; Mitchell RN; Taylor MK; Hasegawa S; Tilney NL; Libby P. 1997. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 100(3):550-7. [PubMed: 9239401]  [MGI Ref ID J:42090]

Naiki M; Yoshida SH; Ansari AA; Bill J; Gershwin ME. 1994. Activation of autoreactive T-cell clones from NZB.H-2bm12 mice. J Autoimmun 7(3):275-90. [PubMed: 7916904]  [MGI Ref ID J:18680]

Naiki M; Yoshida SH; Watanabe Y; Izui S; Ansari AA; Gershwin ME. 1993. The contribution of I-Abm12 to phenotypic and functional alterations among T-cell subsets in NZB mice. J Autoimmun 6(2):131-43. [PubMed: 8388689]  [MGI Ref ID J:4554]

Noorchashm H; Reed AJ; Rostami SY; Mozaffari R; Zekavat G; Koeberlein B; Caton AJ; Naji A. 2006. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 177(11):7715-22. [PubMed: 17114442]  [MGI Ref ID J:140848]

Oshima M; Yokoi T; Deitiker P; Atassi MZ. 1998. T cell responses in EAMG-susceptible and non-susceptible mouse strains after immunization with overlapping peptides encompassing the extracellular part of Torpedo californica acetylcholine receptor alpha chain. Implication to role in myasthenia gravis ofautoimmune T-cell responses against receptor degradation products. Autoimmunity 27(2):79-90. [PubMed: 9583739]  [MGI Ref ID J:46878]

Pereira JP; Kelly LM; Xu Y; Cyster JG. 2009. EBI2 mediates B cell segregation between the outer and centre follicle. Nature :. [PubMed: 19597478]  [MGI Ref ID J:151077]

Perry DJ; Yin Y; Telarico T; Baker HV; Dozmorov I; Perl A; Morel L. 2012. Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor gamma. J Immunol 189(2):793-803. [PubMed: 22711888]  [MGI Ref ID J:189535]

Pobezinsky LA; Angelov GS; Tai X; Jeurling S; Van Laethem F; Feigenbaum L; Park JH; Singer A. 2012. Clonal deletion and the fate of autoreactive thymocytes that survive negative selection. Nat Immunol 13(6):569-78. [PubMed: 22544394]  [MGI Ref ID J:186451]

Poulin LF; Habran C; Stordeur P; Goldman M; McKenzie A; Van Snick J; Renauld JC; Braun MY. 2005. Interleukin-9 stimulates the production of interleukin-5 in CD4+ T cells. Eur Cytokine Netw 16(3):233-9. [PubMed: 16266865]  [MGI Ref ID J:115764]

Poussin MA; Fuller CL; Goluszko E; Reyes VE; Braciale VL; Christadoss P. 2003. Suppressed clinical experimental autoimmune myasthenia gravis in bm12 mice is linked to reduced intracellular calcium mobilization and IL-10 and IFN-gamma release by acetylcholine receptor-specific T cells. J Neuroimmunol 134(1-2):104-10. [PubMed: 12507777]  [MGI Ref ID J:100123]

Poussin MA; Tuzun E; Goluszko E; Scott BG; Yang H; Franco JU; Christadoss P. 2003. B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis. J Immunol 170(8):4389-96. [PubMed: 12682276]  [MGI Ref ID J:125435]

Ronchese F; Brown MA; Germain RN. 1987. Structure-function analysis of the Abm12 beta mutation using site-directed mutagenesis and DNA-mediated gene transfer. J Immunol 139(2):629-38. [PubMed: 3110276]  [MGI Ref ID J:99829]

Rosenberg AS; Sechler JM; Horvath JA; Maniero TG; Bloom ET. 1994. Assessment of alloreactive T cell subpopulations of aged mice in vivo. CD4+ but not CD8+ T cell-mediated rejection response declines with advanced age [published erratum appears in Eur J Immunol 1994 Oct;24(10):2571] Eur J Immunol 24(6):1312-6. [PubMed: 7911422]  [MGI Ref ID J:18905]

Sandner SE; Clarkson MR; Salama AD; Sanchez-Fueyo A; Domenig C; Habicht A; Najafian N; Yagita H; Azuma M; Turka LA; Sayegh MH. 2005. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J Immunol 174(6):3408-15. [PubMed: 15749874]  [MGI Ref ID J:97695]

Sandner SE; Salama AD; Houser SL; Palmer E; Turka LA; Sayegh MH. 2003. New TCR transgenic model for tracking allospecific CD4 T-cell activation and tolerance in vivo. Am J Transplant 3(10):1242-50. [PubMed: 14510697]  [MGI Ref ID J:133237]

Santori FR; Popmihajlov Z; Badovinac VP; Smith C; Radoja S; Harty JT; Vukmanovic S. 2007. TCR beta chain that forms peptide-independent alloreactive TCR transfers reduced reactivity with irrelevant peptide/MHC complex. J Immunol 178(10):6109-14. [PubMed: 17475836]  [MGI Ref ID J:146127]

Sarafova SD; Erman B; Yu Q; Van Laethem F; Guinter T; Sharrow SO; Feigenbaum L; Wildt KF; Ellmeier W; Singer A. 2005. Modulation of coreceptor transcription during positive selection dictates lineage fate independently of TCR/coreceptor specificity. Immunity 23(1):75-87. [PubMed: 16039581]  [MGI Ref ID J:100541]

Selvaggi G; Ricordi C; Podack ER; Inverardi L. 1996. The role of the perforin and Fas pathways of cytotoxicity in skin graft rejection. Transplantation 62(12):1912-5. [PubMed: 8990386]  [MGI Ref ID J:37400]

Sen E; Roy S. 1998. Immunobiological studies on experimental visceral Leishmaniasis. V. The I-A(Bm12) mutation specifies resistance to infection. Scand J Immunol 47(5):431-5. [PubMed: 9627126]  [MGI Ref ID J:48242]

Serody JS; Burkett SE; Panoskaltsis-Mortari A; Ng-Cashin J; McMahon E; Matsushima GK; Lira SA; Cook DN; Blazar BR. 2000. T-lymphocyte production of macrophage inflammatory protein-1alpha is critical to the recruitment of CD8(+) T cells to the liver, lung, and spleen during graft-versus-host disease Blood 96(9):2973-80. [PubMed: 11049973]  [MGI Ref ID J:65501]

Serody JS; Cook DN; Kirby SL; Reap E; Shea TC; Frelinger JA. 1999. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across a class I but not class II major histocompatibility complex barrier. Blood 93(1):43-50. [PubMed: 9864144]  [MGI Ref ID J:51842]

Shao WH; Eisenberg RA; Cohen PL. 2008. The Mer receptor tyrosine kinase is required for the loss of B cell tolerance in the chronic graft-versus-host disease model of systemic lupus erythematosus. J Immunol 180(11):7728-35. [PubMed: 18490777]  [MGI Ref ID J:136377]

Sheng B; Odebralski JM; Smith RT. 1998. All or none peripheral tolerance induction in H-Y antigen-specific TCR transgenic mice. Transpl Immunol 6(2):78-83. [PubMed: 9777695]  [MGI Ref ID J:127670]

Shimizu K; Libby P; Shubiki R; Sakuma M; Wang Y; Asano K; Mitchell RN; Simon DI. 2008. Leukocyte integrin Mac-1 promotes acute cardiac allograft rejection. Circulation 117(15):1997-2008. [PubMed: 18378617]  [MGI Ref ID J:153298]

Shono Y; Ueha S; Wang Y; Abe J; Kurachi M; Matsuno Y; Sugiyama T; Nagasawa T; Imamura M; Matsushima K. 2010. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood 115(26):5401-11. [PubMed: 20354171]  [MGI Ref ID J:162817]

Tanaka M; Sydow K; Gunawan F; Jacobi J; Tsao PS; Robbins RC; Cooke JP. 2005. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation 112(11):1549-56. [PubMed: 16144995]  [MGI Ref ID J:118229]

Thangavelu G; Gill RG; Boon L; Ellestad KK; Anderson CC. 2013. Control of in vivo collateral damage generated by T cell immunity. J Immunol 191(4):1686-91. [PubMed: 23851694]  [MGI Ref ID J:205689]

Tomura M; Nakatani I; Murachi M; Tai XG; Toyo-oka K; Fujiwara H. 1997. Suppression of allograft responses induced by interleukin-6, which selectively modulates interferon-gamma but not interleukin-2 production. Transplantation 64(5):757-63. [PubMed: 9311716]  [MGI Ref ID J:43100]

Ueno T; Habicht A; Clarkson MR; Albin MJ; Yamaura K; Boenisch O; Popoola J; Wang Y; Yagita H; Akiba H; Ansari MJ; Yang J; Turka LA; Rothstein DM; Padera RF; Najafian N; Sayegh MH. 2008. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest 118(2):742-51. [PubMed: 18172549]  [MGI Ref ID J:131045]

Varona R; Cadenas V; Gomez L; Martinez-A C; Marquez G. 2005. CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses. Blood 106(1):18-26. [PubMed: 15774622]  [MGI Ref ID J:107449]

Vogtenhuber C; Bucher C; Highfill SL; Koch LK; Goren E; Panoskaltsis-Mortari A; Taylor PA; Farrar MA; Blazar BR. 2010. Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses. Blood 116(3):466-74. [PubMed: 20442366]  [MGI Ref ID J:162794]

Wang S; Xu X; Xie A; Li J; Ye P; Liu Z; Wu J; Rui L; Xia J. 2012. Anti-interleukin-12/23p40 antibody attenuates chronic rejection of cardiac allografts partly via inhibition gammadeltaT cells. Clin Exp Immunol 169(3):320-9. [PubMed: 22861372]  [MGI Ref ID J:188287]

Watanabe T; Kawamura T; Kawamura H; Haga M; Shirai K; Watanabe H ; Eguchi S ; Abo T. 1997. Intermediate TCR cells in mouse lung: their effector function to induce pneumonitis in mice with autoimmune-like graft-versus-host disease. J Immunol 158(12):5805-14. [PubMed: 9190932]  [MGI Ref ID J:40937]

Watanabe Y; Yoshida SH; Ansari AA; Gershwin ME. 1994. The contribution of H-2bm12 and non H-2 background genes on murine lupus in NZB.H-2bm12/b mice. J Autoimmun 7(2):153-64. [PubMed: 8037836]  [MGI Ref ID J:17841]

Widera G; Flavell RA. 1984. The nucleotide sequence of the murine I-E beta b immune response gene: evidence for gene conversion events in class II genes of the major histocompatibility complex. EMBO J 3(6):1221-5. [PubMed: 6086309]  [MGI Ref ID J:99767]

Williams CA; Murray SE; Weinberg AD; Parker DC. 2007. OX40-mediated differentiation to effector function requires IL-2 receptor signaling but not CD28, CD40, IL-12Rbeta2, or T-bet. J Immunol 178(12):7694-702. [PubMed: 17548606]  [MGI Ref ID J:148588]

Xing Y; Sonner JM; Eger EI 2nd; Cascio M; Sessler DI. 2004. Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. Anesthesiology 101(2):544-6. [PubMed: 15277941]  [MGI Ref ID J:105413]

Yamada A; Salama AD; Sho M; Najafian N; Ito T; Forman JP; Kewalramani R; Sandner S; Harada H; Clarkson MR; Mandelbrot DA; Sharpe AH; Oshima H; Yagita H; Chalasani G; Lakkis FG; Auchincloss H Jr; Sayegh MH. 2005. CD70 signaling is critical for CD28-independent CD8+ T cell-mediated alloimmune responses in vivo. J Immunol 174(3):1357-64. [PubMed: 15661893]  [MGI Ref ID J:136519]

Yang B; McIntosh KR; Drachman DB. 1998. How subtle differences in MHC class II affect the severity of experimental myasthenia gravis. Clin Immunol Immunopathol 86(1):45-58. [PubMed: 9434796]  [MGI Ref ID J:45094]

Yang J; Popoola J; Khandwala S; Vadivel N; Vanguri V; Yuan X; Dada S; Guleria I; Tian C; Ansari MJ; Shin T; Yagita H; Azuma M; Sayegh MH; Chandraker A. 2008. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 117(5):660-9. [PubMed: 18212277]  [MGI Ref ID J:145084]

Yang J; Riella LV; Chock S; Liu T; Zhao X; Yuan X; Paterson AM; Watanabe T; Vanguri V; Yagita H; Azuma M; Blazar BR; Freeman GJ; Rodig SJ; Sharpe AH; Chandraker A; Sayegh MH. 2011. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 187(3):1113-9. [PubMed: 21697455]  [MGI Ref ID J:179116]

Yeung MY; McGrath MM; Nakayama M; Shimizu T; Boenisch O; Magee CN; Abdoli R; Akiba H; Ueno T; Turka LA; Najafian N. 2013. Interruption of dendritic cell-mediated TIM-4 signaling induces regulatory T cells and promotes skin allograft survival. J Immunol 191(8):4447-55. [PubMed: 24038092]  [MGI Ref ID J:206275]

Yoshimoto T; Min B; Sugimoto T; Hayashi N; Ishikawa Y; Sasaki Y; Hata H; Takeda K; Okumura K; Van Kaer L; Paul WE; Nakanishi K. 2003. Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med 197(8):997-1005. [PubMed: 12695491]  [MGI Ref ID J:120694]

Zhao Z; Burkly LC; Campbell S; Schwartz N; Molano A; Choudhury A; Eisenberg RA; Michaelson JS; Putterman C. 2007. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 179(11):7949-58. [PubMed: 18025243]  [MGI Ref ID J:154900]

Mc1re-J related

Anderson MG; Hawes NL; Trantow CM; Chang B; John SW. 2008. Iris phenotypes and pigment dispersion caused by genes influencing pigmentation. Pigment Cell Melanoma Res 21(5):565-78. [PubMed: 18715234]  [MGI Ref ID J:141035]

Mathewson N; Toubai T; Kapeles S; Sun Y; Oravecz-Wilson K; Tamaki H; Wang Y; Hou G; Sun Y; Reddy P. 2013. Neddylation plays an important role in the regulation of murine and human dendritic cell function. Blood 122(12):2062-73. [PubMed: 23863900]  [MGI Ref ID J:202233]

Samples RM; Donahue LR; Curtain M; Ward-Bailey PF. 2004. A remutation to Mc1r<e> named recessive yellow Jackson (e-J) MGI Direct Data Submission :.  [MGI Ref ID J:90328]

Xing Y; Sonner JM; Eger EI 2nd; Cascio M; Sessler DI. 2004. Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. Anesthesiology 101(2):544-6. [PubMed: 15277941]  [MGI Ref ID J:105413]

Health & husbandry

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls


Pricing for USA, Canada and Mexico shipping destinations View International Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $3175.00
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

Pricing for International shipping destinations View USA Canada and Mexico Pricing

Cryopreserved

Cryopreserved Mice - Ready for Recovery

Price (US dollars $)
Cryorecovery* $4127.50
Animals Provided

At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

Supply Notes

  • Cryorecovery - Standard.
    Progeny testing is not required.
    The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

    Cryorecovery to establish a Dedicated Supply for greater quantities of mice
    Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).

View USA Canada and Mexico Pricing View International Pricing

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.

General Supply Notes

  • View the complete collection of spontaneous mutants in the Mouse Mutant Resource.

Control Information

  Control
   Heterozygote from the colony
 
  Considerations for Choosing Controls
  Control Pricing Information for Genetically Engineered Mutant Strains.
 

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.


See Terms of Use tab for General Terms and Conditions


The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.
Ordering Information
JAX® Mice
Surgical and Preconditioning Services
JAX® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use


General Terms and Conditions


Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:207-288-6470

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.


(6.5)